Completed
PHASE2
INTERVENTIONAL
NCT01667406
The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
We want to find out if kisspeptin is successful in stimulating oocyte maturation when it is used as a 'trigger' injection during IVF therapy for infertility.
Detailed Description
Participants in the study will have a standard Gonadotrophin Releasing Hormone (GnRH) antagonist IVF cycle, but instead of having a trigger injection of hCG (human chorionic gonadotrophin) they will be randomised to receive one of 4 doses of kisspeptin injection. Oocytes will be retrieved and graded by an embryologist to see whether or not they have matured. The reproductive hormones Luteinising hormone, follicle stimulating hormone, oestradiol and progesterone will also be measured
Interventions
Name:
Kisspeptin 1.6nmol/kg
Type:
DRUG
Description:
single kisspeptin dose 1.6 nmol/kg subcutaneously
Name:
Kisspeptin 3.2nmol/kg
Type:
DRUG
Description:
single kisspeptin dose 3.2 nmol/kg subcutaneously
Name:
Kisspeptin 6.4nmol/kg
Type:
DRUG
Description:
single kisspeptin dose 6.4 nmol/kg subcutaneously
Name:
Kisspeptin 9.6nmol/kg
Type:
DRUG
Description:
single kisspeptin dose 9.6 nmol/kg subcutaneously
Name:
Kisspeptin 12.8nmol/kg
Type:
DRUG
Description:
single kisspeptin dose 12.8 nmol/kg subcutaneously
Name:
Kisspeptin 9.6 nmol/kg double
Type:
DRUG
Description:
kisspeptin dose 9.6 nmol/kg given twice 10hrs apart subcutaneously
Name:
Kisspeptin 9.6 nmol/kg + saline
Type:
DRUG
Description:
kisspeptin dose 9.6 nmol/kg subcutaneously and saline subcutaneously, 10hrs apart
Primary Outcomes
Measure:
Percentage of Oocyte Maturation
TimeFrame:
36 hours post Kisspeptin-54 trigger injection
Description:
This was assessed by oocyte yield (percentage of mature \[metaphase 2; M2\] oocytes collected from the number of follicles ≥ 14 mm on final ultrasound scan prior to kisspeptin-54 trigger administration
Trial Information
NCT ID
NCT01667406
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Imperial College London
Last Updated
December 15, 2025